DealsJun 18, 2026, 08:06 AM
Denali Therapeutics Sells PRV for $195 Million
AI Summary
Denali Therapeutics Inc. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million. The PRV was awarded by the FDA following the approval of AVLAYAH™ for Hunter syndrome. The proceeds from this sale will be used to advance Denali's pipeline of treatments for lysosomal storage disorders and neurodegenerative diseases. The deal is subject to standard closing conditions, including regulatory review.
Key Highlights
- Denali Therapeutics to sell Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million.
- The PRV was awarded following the FDA approval of AVLAYAH™ (tividenofusp alfa) for Hunter syndrome.
- Proceeds will support the advancement of Denali's clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.
- The transaction is subject to customary closing conditions, including antitrust review under the Hart-Scott-Rodino Act.
Price Impact
More from DNLI